Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
336 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05455606 | Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment | active not recruiting | N/A | 1,284 | SWOG Cancer Research NetworkNETWORK | 2 | Jan 22, 2026 |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer(S1216) | completed | Phase 3 | 1,313 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03654768 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 81 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05040360 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 141 | SWOG Cancer Research NetworkNETWORK | 3 | Dec 15, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT03694002 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery(S0931) | completed | Phase 3 | 1,545 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 16, 2025 | clinicaltrials |
| NCT03678025 | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | recruiting | Phase 3 | 1,273 | SWOG Cancer Research NetworkNETWORK | 5 | Sep 11, 2025 | clinicaltrials |
| NCT03499808 | S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | completed | Phase 2 | 43 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT01359592 | S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 159 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 17, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT01309672 | S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | completed | Phase 2 | 41 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 26, 2025 | clinicaltrials |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | Phase 2 | 143 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01224665 | S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer | completed | N/A | 658 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 29, 2024 | clinicaltrials |
| NCT02177695 | S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer(COXEN) | completed | Phase 2 | 237 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03971474 | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | completed | Phase 2 | 166 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04173507 | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | completed | Phase 2 | 47 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05364645 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03887702 | Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors | terminated | Phase 3 | 4 | SWOG Cancer Research NetworkNETWORK | 2 | May 20, 2024 | clinicaltrials |
| NCT04205955 | Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors | completed | Phase 2 | 95 | SWOG Cancer Research NetworkNETWORK | 2 | May 1, 2024 | clinicaltrials |
| NCT01959139 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 126 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 9, 2024 | clinicaltrials |
| NCT01946516 | S1204, Viral Screening in Newly Diagnosed Cancer Patients | completed | — | 3,051 | SWOG Cancer Research NetworkNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04194528 | S1916 Digital Medicine Program for Pain Control in Cancer Patients | terminated | N/A | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 27, 2023 | clinicaltrials |
| NCT03373760 | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | completed | Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 9, 2023 | clinicaltrials |
| NCT02154490 | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | completed | — | 1,864 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 1, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT00840177 | S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | 115 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT01925131 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 50 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT02270450 | S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction | completed | N/A | 221 | SWOG Cancer Research NetworkNETWORK | 5 | Mar 30, 2023 | clinicaltrials |
| NCT02728804 | S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer | completed | — | 380 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 26, 2023 | clinicaltrials |
| NCT00492856 | S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 105 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00551460 | S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | completed | Phase 2 | 78 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00004124 | S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | completed | Phase 3 | 983 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 30, 2022 | clinicaltrials |
| NCT01598298 | S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy | completed | Phase 3 | 299 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 16, 2022 | clinicaltrials |
| NCT01416688 | S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride | completed | — | 146 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 15, 2022 | clinicaltrials |
| NCT01535066 | S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer | completed | N/A | 226 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02728596 | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)(TrACER) | completed | N/A | 3,665 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 20, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT00822120 | S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma | completed | Phase 2 | 371 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 18, 2022 | clinicaltrials |
| NCT00070018 | S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma | completed | Phase 2 | 46 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01412879 | S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 53 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 29, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials